Antibody

AntibodystaleInstitut für Klinische Krebsfor…Phase 2

임상시험 1상태 DISCONTINUED

Glofitamab as Consolidation therapy (Glofitamab as Consolidation therapy)

Relapsed /Refractory DLBCL · FRα

AntibodystaleInstitut für Klinische Krebsfor…Phase 2

Glofitamab, Gemcitabine, and Oxaliplatin as Induction Therapy (Glofitamab, Gemcitabine, and Oxaliplatin as Induction Therapy)

Relapsed /Refractory DLBCL · FRα

AntibodystaleChinese Academy of Medical Scie…Phase 2

Ibrutinib Combined With Rituximab (Ibrutinib Combined With Rituximab)

DLBCL; MYD88 Gene Mutation · FRα

AntibodystaleSanofiPhase 2

Isatuximab SC-OBDS (Isatuximab SC-OBDS)

Plasma Cell Myeloma Refractory · FRα

AntibodystaleMonopteros Therapeutics Inc.Phase 1

pembrolizumab (Keytruda, MPT-0118 + pembrolizumab)

Solid Tumor, Adult; Advanced Solid Tumor · FRα

#FR#Antibody#Phase1#항체#면역항체+5

AntibodystaleRochePhase 2

Melphalan/HDS Followed by Consolidation Treatment with Trifluridine-tipiracil plus Bevacizumab (Melphalan/HDS Followed by Consolidation Treatment with Trifluridine-tipiracil plus Bevacizumab)

Refractory Metastatic Colorectal Cancer · FRα

daratumumab (Darzalex, Mitoxantrone hydrochloride liposome/Dexamethasone/daratumumab)

Relapsed/Refractory Multiple Myeloma · FRα

AntibodystaleAbGenomics B.V Taiwan BranchPhase 2

Neihulizumab Treatment (Neihulizumab Treatment)

Steroid-refractory aGvHD Subsequent to Allogeneic Hematopoietic Cell Transplantation · FRα

AntibodystaleRochePhase 2

임상시험 1상태 DISCONTINUED

Orelabrutinib and Rituximab (Orelabrutinib and Rituximab)

Follicular Lymphoma; Relapsed and Refractory Follicular Lymphoma · FRα

AntibodystaleSCRI Development Innovations, L…Phase 1

PTK787/ZK222584 and Bevacizumab (PTK787/ZK222584 and Bevacizumab)

Refractory Malignancy; Advanced Malignancies · FRα

#FR#Antibody#Phase1#항체#면역항체+4

daratumumab (Darzalex, QL2109 or Daratumumab)

Relapsed or Refractory Multiple Myeloma · FRα

AntibodystaleRegeneron PharmaceuticalsPhase 2

REGN17372+Linvoseltamab (REGN17372+Linvoseltamab)

Relapsed Refractory Multiple Myeloma (RRMM) · FRα

AntibodystaleZibo Municipal HospitalPhase 2

SBRT combined with Tislelizumab followed by Tislelizumab (SBRT combined with Tislelizumab followed by Tislelizumab)

NSCLC; Tislelizumab · FRα

Teclistamab Monotherapy (Teclistamab Monotherapy)

Relapse Multiple Myeloma; Refractory Multiple Myeloma · FRα

FDA-approved (Teclistamab, Teclistamab(FDA-approved))

Multiple Myeloma; Cytokine Release Syndrome · FRα

AntibodystaleHoffmann-La RochePhase 3

임상시험 1상태 DISCONTINUED

Tociluzumab (Tociluzumab)

Relapsed or Refractory Follicular Lymphoma · FRα

#FR#Antibody#Phase3#항체#면역항체+3

AntibodystaleRochePhase 2

Trifluridine-tipiracil plus Bevacizumab Alone (Trifluridine-tipiracil plus Bevacizumab Alone)

Refractory Metastatic Colorectal Cancer · FRα

AntibodystaleNational Cancer Institute (NCI)Phase 1

aflibercept (Eylea, VEGF Trap-Eye, Eylea HD, Ziv-Aflibercept)

Clinical Stage IV Cutaneous Melanoma AJCC v8; Metastatic Colorectal Carcinoma · FRα

#FR#Antibody#Phase1#항체#면역항체+4

AntibodystaleNational Cancer Institute (NCI)Phase 2

apolizumab (apolizumab)

Noncontiguous Stage II Small Lymphocytic Lymphoma; Recurrent Small Lymphocytic Lymphoma · FRα